Teva launches ‘Patient First’ project
WASHINGTON The world’s largest generic drug maker has started an initiative to tell stories of Americans who have difficulty paying for their prescription medications, and push for a regulatory approval pathway for biosimilars.
Teva Pharmaceuticals USA announced Thursday the “Patient First” project, part of its broader Year of Affordable Healthcare campaign.
One story is of Rob Day, who was diagnosed at age 19 with the rare blood disorder paroxysmal nocturnal hemoglobinuria, for which he must take an unspecified biotech drug that costs him $389,000 a year. Teva said a Food and Drug Administration approval pathway for biosimilars would help lower prices for drugs like the one Day takes.
Stiefel zaps acne segment with ‘leave-on’ treatment
DULUTH, Ga. Stiefel Labs, a GlaxoSmithKline company, launched one of the first “leave-on” treatments for acne care, PanOxyl, as a line extension to the company’s acne-care bar and wash.
The formulation is not greasy as compared with spot treatments, and blends into the skin upon application. The new formulation delivers 10% Benzoyl Peroxide in a foam delivery.
In addition to consumer ad support, Stiefel will be fielding its 200-strong dedicated representatives to detail dermatologists.
Stiefel also introduced its Sensitive Sarna eczema itch relief kit, an all-in-one kit that includes a cleanse, itch relief and moisturizer.
New directors elected to NACDS Foundation board
ALEXANDRIA, Va. The National Association of Chain Drug Stores has elected three new directors to the board of the NACDS Foundation.
Jim VanLieshout, VP retail sales with Apotex; Alice Swearingen, VP channel development sales for GlaxoSmithKline; and Chris Dimos, president of pharmacy operations for Supervalu, will fill vacancies on the board, which consists of 22 members.
“We are pleased to welcome the three new members to the NACDS Foundation board of directors,” said Edith Rosato, president of the NACDS Foundation.
“They will continue the strong representation on the board of chains and suppliers alike. We value their expertise, dedication and commitment to the industry, and we look forward to working together for the good of the public and the patients served by community pharmacy.”